Stops False Drug Approval Delays

Official: Stop STALLING Act

IntroducedN/A

Why This Matters

This bill allows the Federal Trade Commission to combat false petitions that delay the approval of generic drugs and biosimilars.

If you rely on generic drugs, this bill helps ensure they are approved faster by stopping false delays.

Affects: This bill affects pharmaceutical companies and consumers seeking access to affordable medications.

What changes is this bill making?

1. This bill allows the Federal Trade Commission to take action against false petitions that delay drug approvals. 2. It defines a 'sham' petition as one that is baseless and intended to interfere with a competitor's business. 3. The bill enables civil actions against those who submit these false petitions, seeking penalties and other relief. 4. If the Secretary of Health and Human Services identifies a petition as intended to delay approval, it can be presumed sham. 5. This legislation aims to promote competition and ensure that legitimate health concerns are addressed efficiently.

Who is affected?

This bill affects pharmaceutical companies and consumers seeking access to affordable medications.